SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Globe Newswire•06/08/2026•16:05 ET
0
Whiz Insights
* Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.
* Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.
Get started
Create a free account to read the full story.